Pancreatic Cancer Survey for all Patients, Survivors and Caregivers 

 Approval for a new treatment drug is under review ... your experience, past or present, with pancreatic cancer is a key element in the recommendation of a new treatment drug for pancreatic cancer.

Can you please help us by taking the time to complete a short survey?

Canadian approval of Abraxane is being considered for the treatment of advanced pancreatic cancer. Abraxane works by delaying tumor growth. Abraxane is intended to be used with gemcitabine, another chemotherapy drug, in patients with pancreatic cancer that has spread to other parts of the body. 

Abraxane, created by Celgene, is currently approved by the Food and Drug Administration (FDA) in the United States and last week, was approved by the European Union (EU) to be part of a chemotherapy regimen to fight late-stage pancreatic cancer.

The following survey will be used as part of Pancreatic Cancer Canada and Craig's Cause Pancreatic Cancer Society's joint Patient Evidence Submission to the pan-Canadian Oncology Drug Review (pCODR). PCODR evaluates cancer drugs and makes recommendations to the provinces and territories to guide their drug funding decisions. Your participation will help pCODR understand the patient and caregiver perspectives concerning the experience and access to pancreatic cancer therapies. 

Thank you for your willingness to contribute to the following survey:

Click here to view this message as HTML in your browser.

Click here to forward this message.

Click here to change your email preferences.